Truist analyst Jailendra Singh raised the firm’s price target on Doximity (DOCS) to $61 from $52 and keeps a Hold rating on the shares as part of a broader research note previewing Q2 results for Health Care IT / Digital Health sector names. Despite the strong YTD outperformance in shares, investor sentiment still remains relatively mixed, with the interest level from long-onlies/generalist investors seen as “relatively selective”, the analyst tells investors in a research note. HCIT space has also benefited from the lack of direct tariff exposure and other macro uncertainty as well as renewed capital market activity, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity upgraded to Outperform from In Line at Evercore ISI
- Doximity price target raised to $62 from $55 at BofA
- Doximity’s Hold Rating: Balancing Optimism with Macroeconomic Caution
- Potential Regulatory Changes in Pharmaceutical Advertising Boost Doximity’s Prospects
- Doximity up 4% after Bloomberg report on pharma ad crackdown